Ciprofloxacin hydrate | 128074-76-0

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 喹啉及其衍生物
• 英文名称: Ciprofloxacin hydrate
• 英文别名: 1-cyclopropyl-6-fluoro-4-oxo-7-piperazin-1-ylquinoline-3-carboxylic acid;hydrate
• CAS: 128074-76-0
• 化学式: C17H20FN3O4
• 分子量: 349.4
• InChiKey: AYXRASQXGJILAA-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.76
• 重原子数：
  25
• 可旋转键数：
  3
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.41
• 拓扑面积：
  73.9
• 氢给体数：
  3
• 氢受体数：
  8

文献信息

• Ciprofloxacin otic composition and kits and method for using same
  申请人：ALK-ABELLÓ, INC.

  公开号：US11246863B2

  公开（公告）日：2022-02-15

  Disclosed herein are otic product kits for administration of a sterilized formulation. In some embodiments, the otic product kit comprises: an aseptic container containing the sterilized formulation; a syringe; and an administration needle connectable to the syringe, wherein the sterilized formulation comprising: from about 5.5 wt % to about 6.5 wt % multiparticulate ciprofloxacin; from about 15 wt % to about 17 wt % poloxamer 407; and water. Also disclosed herein are methods of preparing and administrating the sterilized formulation. In some embodiments, the method comprising (1) transferring the sterilized otic formulation from an aseptic container to a syringe through a preparation needle; (2) replacing the preparation needle with an administration needle; and (3) injecting the sterilized otic formulation from the syringe through the administration needle into the ear of a patient.

  本文公开了用于施用灭菌制剂的耳科产品套件。在一些实施例中，耳科产品套件包括：无菌容器，内装灭菌制剂；注射器；以及可与注射器连接的给药针头，其中灭菌制剂包括：约 5.5 重量％至约 6.5 重量％的多颗粒环丙沙星；约 15 重量％至约 17 重量％的 poloxamer 407；以及水。本文还公开了制备和施用灭菌制剂的方法。在一些实施方案中，该方法包括：(1)将灭菌耳用制剂从无菌容器通过制备针转移到注射器中；(2)用给药针替换制备针；以及(3)将灭菌耳用制剂从注射器通过给药针注射到患者的耳朵中。
• MODULATION OF GEL TEMPERATURE OF POLOXAMER-CONTAINING FORMULATIONS
  申请人：Otonomy, Inc.

  公开号：EP2490722A2

  公开（公告）日：2012-08-29
• STERILIZATION OF CIPROFLOXACIN COMPOSITION
  申请人：Otonomy, Inc.

  公开号：EP3164115A1

  公开（公告）日：2017-05-10
• Antiretroviral combination therapy
  申请人：Allaway Graham

  公开号：US20080039428A1

  公开（公告）日：2008-02-14

  The present invention provides combinations comprising a viral maturation inhibitor and another therapeutically effective pharmaceutical agent. The invention is also directed to methods of treating a viral infection by administering such combinations.
• Modulation of Gel Temperature of Poloxamer-Containing Formulations
  申请人：Ye Qiang

  公开号：US20120277199A1

  公开（公告）日：2012-11-01

  Disclosed herein are methods for modulation of gel temperature of poloxamer-containing formulations. Also described herein are sustained release pharmaceutical formulations that gel upon contact with the body and are administered by direct application of these compositions and formulations onto or via perfusion into the targeted structure(s).